Salesforce Inc (NYSE:CRM, ETR:FOO) shares moved lower after the customer relationship management (CRM) software provider reported a revenue miss for the fourth quarter and issued conservative guidance.
For Q4, revenue of $9.99 billion marked an 8% year-over-year increase by missed estimates of $10.04 due to a $75 million FX headwind.
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has announced the publication of a new study in Nature Neuroscience that demonstrates promising results for its nasal anti-CD3 therapy in treating traumatic brain injury (TBI).
The study revealed that nasal administration of Tiziana's anti-CD3 therapy significantly modulated neuroinflammatory responses, resulting in improved neurological outcomes.
Ideal Power Inc (NASDAQ:IPWR) ended its fourth quarter with nearly $16 million in cash as it looks to commercial sales of its B-TRAN product later this year.
During the quarter, the company secured its first design win for solid-state circuit breakers (SSCB) with a major Asian circuit protection equipment manufacturer.
Medicus Pharma (NASDAQ:MDCX) has announced the submission of its Phase 2 clinical study design, evaluating its non-invasive therapy targeting basal cell carcinoma (BCC) of the skin, to the United Arab Emirates (UAE) Department of Health.
The study, SKNJCT-004, is set to enroll 36 participants across four leading medical institutions in the UAE: the Cleveland Clinic Abu Dhabi, Sheikh Shakbout Medical City, Burjeel Medical City, and American Hospital of Dubai.
Haleon PLC's (LSE:HLN, NYSE:HLN) prelims have reassured investors, with earnings per share (EPS) beating expectations by 6% in the second half of 2024, according to analysts - although the shares succumbed to a bout of profit taking in their wake.
The consumer health giant reported 5% organic growth for the year, slightly ahead of market forecasts, Stifel said.
Haleon PLC (LSE:HLN, NYSE:HLN) shares fell 3.2% in early trading as investors saw little in the results to justify further gains at current valuations.
While full-year sales and profits met expectations, analysts noted a lack of clear catalysts.
Nvidia Corp (NASDAQ:NVDA, ETR:NVD) shares fell in pre-market trading as investors weighed strong fourth-quarter earnings against signs of slowing growth.
The chipmaker posted revenue of $39.33 billion, ahead of analyst forecasts, with adjusted earnings per share of $0.89 also beating expectations.